🔎 Trials Near Me

Beranda › Limfoma Sel Mantel › Connecticut

Uji klinis Limfoma Sel Mantel di Connecticut

6 studi untuk Limfoma Sel Mantel mencari peserta di lokasi di Connecticut.

Kota di Connecticut

Teks studi resmi (Bahasa Inggris)

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

  • Smilow Cancer Hospital-Derby Care Center, Derby
  • Smilow Cancer Hospital Care Center-Fairfield, Fairfield
  • Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
  • dan 10 lainnya
Menerima pesertaFase 3
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05976763

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  • Yale University Yale Cancer Center, New Haven
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06742996

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Yale University School of Medicine - Yale Cancer Center, New Haven
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328

DALY II USA/ MB-CART2019.1 for DLBCL

  • Yale University, New Haven
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • Yale Cancer Center, New Haven
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT05131022

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Hartford
  • Massive Bio SYNERGY-AI site, Norwalk
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.